Business Context and Reporting Period
Company: Artiva Biotherapeutics, Inc. (ARTV)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Artiva is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company's lead product candidate, AlloNK (AB-101), is in early clinical development, with a focus on refractory rheumatoid arthritis (RA). The company has no products approved for commercial sale and has incurred net losses since inception.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $251 |
| Net Loss | $(21,528) | $(17,472) | $(63,093) | $(49,278) |
| Net Loss Per Share (Basic/Diluted) | $(0.88) | $(0.92) | $(2.59) | $(7.16) |
| Operating Expenses | $22,897 | $18,335 | $67,878 | $49,266 |
| Research & Development (R&D) | $17,633 | $13,524 | $52,546 | $37,011 |
| General & Administrative (G&A) | $5,264 | $4,811 | $15,332 | $12,255 |
| Cash, Cash Equivalents & Investments | $122,968 | $185,428 | $122,968 | $185,428 |
| Accumulated Deficit | $(309,777) | $(230,589) | $(309,777) | $(230,589) |
| Net Cash Used in Operating Activities (9 Months) | $(62,025) | $(40,382) | $(62,025) | $(40,382) |
Material Changes vs. Prior Period
- Revenue: The company reported zero revenue for the three and nine months ended September 30, 2025, compared to $251,000 in the same period in 2024. The prior year revenue was derived from development support activities under an agreement with GC Cell.
- Net Loss: Net loss increased by approximately 23% for the quarter and 28% for the nine-month period compared to the prior year, driven primarily by increased R&D and G&A expenses.
- R&D Expenses: Increased by $4.1 million for the quarter and $15.5 million for the nine months. This was primarily due to higher external costs for the AlloNK clinical trials and increased internal personnel costs.
- Other Income: Other income increased significantly due to the absence of a $3.6 million loss from the change in fair value of Simple Agreements for Future Equity (SAFEs) in 2024, which converted to common stock upon the company's IPO in July 2024.
- Liquidity: Cash, cash equivalents, and short-term investments decreased from $185.4 million at December 31, 2024, to $123.0 million at September 30, 2025, reflecting operating cash burn.
Guidance, Outlook, and Risks
- Clinical Progress: In August 2025, the company treated the first patient in a global Phase 2a basket trial for AlloNK in combination with rituximab for refractory RA and other autoimmune diseases. In October 2025, the FDA granted Fast Track Designation to AlloNK for refractory RA.
- Outlook: Management expects to share initial safety and translational data for over 20 patients in mid-November 2025 and clinical response data for refractory RA patients in the first half of 2026. The company plans regulatory interactions with the FDA in the first half of 2026 regarding pivotal trial design.
- Liquidity Position: As of September 30, 2025, the company had $123.0 million in cash and investments. Management believes this is sufficient to fund planned operations into the second quarter of 2027. However, the company expects to continue incurring significant losses and will require substantial additional funding to complete development and commercialization.
- Key Risks:
- Capital Needs: Failure to raise additional capital could force the company to delay or eliminate R&D programs.
- Clinical Uncertainty: No NK cell-based therapy has been approved for commercial use. Clinical trials are expensive and have uncertain outcomes.
- Manufacturing: Reliance on third-party manufacturers (GC Cell) and the complexity of cell therapy manufacturing pose supply risks.
- Regulatory: Regulatory pathways for cell therapies in autoimmune diseases are evolving and uncertain.
- Management Change: On November 10, 2025, the company announced the resignation of its Chief Financial Officer, Neha Krishnamohan, effective no later than December 31, 2025. She will serve as a consultant through February 28, 2026.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $123 million cash balance and the projection that funds will last into Q2 2027 given the current burn rate of ~$62 million per nine months.
- Clinical Trial Enrollment: Monitor the November 2025 data readout for the Phase 2a basket trial to assess safety and early efficacy signals for AlloNK in autoimmune diseases.
- Capital Raising: Watch for announcements regarding the "at-the-market" (ATM) offering program (up to $12 million authorized in August 2025) or other equity/debt financings to fund operations beyond 2027.
- Executive Transition: Track the appointment of a permanent replacement for the departing CFO to ensure financial reporting continuity.
- Collaboration Milestones: Review the status of agreements with GC Cell, specifically regarding milestone payments and royalty obligations, as these impact future cash outflows.